Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome

[1]  M. Elisaf,et al.  Clinical research Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome , 2008 .

[2]  D. Mikhailidis,et al.  Do we need to consider inflammatory markers when we treat atherosclerotic disease? , 2008, Atherosclerosis.

[3]  D. Mikhailidis,et al.  Multiple actions of high-density lipoprotein , 2008, Current opinion in cardiology.

[4]  M. Kostapanos,et al.  The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome , 2008, Diabetes, obesity & metabolism.

[5]  A. Nègre-Salvayre,et al.  Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. , 2008, Atherosclerosis.

[6]  M. Laakso,et al.  Association of C-Reactive Protein, Interleukin-1 Receptor Antagonist and Adiponectin with the Metabolic Syndrome , 2007, Mediators of inflammation.

[7]  R. Wolfert,et al.  Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Banach,et al.  Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation , 2007, Archivum Immunologiae et Therapiae Experimentalis.

[9]  E. Liberopoulos,et al.  The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. , 2007, Atherosclerosis.

[10]  G. Berglund,et al.  Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Anand Rohatgi,et al.  HDL cholesterol: physiology, pathophysiology, and management. , 2007, Current problems in cardiology.

[12]  D. Mikhailidis,et al.  Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles , 2007, Expert opinion on biological therapy.

[13]  B. Hansel,et al.  Alterations in lipoprotein defense against oxidative stress in metabolic syndrome , 2006, Current atherosclerosis reports.

[14]  R. James.  A long and winding road: defining the biological role and clinical importance of paraoxonases , 2006, Clinical chemistry and laboratory medicine.

[15]  M. Elisaf,et al.  Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. , 2006, Metabolism: clinical and experimental.

[16]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[17]  A. Kontush,et al.  Antiatherogenic small, dense HDL—guardian angel of the arterial wall? , 2006, Nature Clinical Practice Cardiovascular Medicine.

[18]  P Hugh R Barrett,et al.  High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. , 2006, The Journal of clinical endocrinology and metabolism.

[19]  R. D'Agostino,et al.  Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study , 2005, Circulation.

[20]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[21]  G. Winkler,et al.  Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. , 2005, Diabetes & metabolism.

[22]  M. Elisaf,et al.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. , 2005, Clinical chemistry.

[23]  Serkalem Demissie,et al.  Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[24]  D. Mikhailidis,et al.  Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects , 2005, Stroke.

[25]  A. Morabia,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(4):2264–2269 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1295 Small, Dense Lipoprotein Particles and Reduced Paraoxonase-1 in Patients with th , 2005 .

[26]  M. Elisaf,et al.  Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[27]  B. Hansel,et al.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia , 2005, Diabetologia.

[28]  M. Elisaf,et al.  Evaluation of Methods for the Measurement of Low-Density Lipoprotein Cholesterol , 2005, Journal of cardiovascular pharmacology and therapeutics.

[29]  L. Cupples,et al.  High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[30]  S. Daskalopoulou,et al.  Prevention and Treatment of the Metabolic Syndrome , 2004, Angiology.

[31]  Philippe Giral,et al.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. , 2004, The Journal of clinical endocrinology and metabolism.

[32]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[33]  G. Assmann,et al.  Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* , 2004, Current medical research and opinion.

[34]  J. Fruchart,et al.  Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. , 2004, Archives of medical research.

[35]  F. Danielbrites.  Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia , 2004 .

[36]  A. Tselepis,et al.  Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. , 2003, Biochemical pharmacology.

[37]  S. Deeb,et al.  Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. , 2003, Journal of lipid research.

[38]  Gerard E. Dallal,et al.  Change in &agr;1 HDL Concentration Predicts Progression in Coronary Artery Stenosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[39]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[40]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[41]  G. Fonarow,et al.  Paraoxonase and coronary heart disease. , 2002, Current opinion in lipidology.

[42]  J. Goudevenos,et al.  Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[43]  S.-M. Kim,et al.  Glycation impairs high-density lipoprotein function , 2000, Diabetologia.

[44]  A. Boulton,et al.  Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. , 2000, Clinical science.

[45]  R. Hegele,et al.  Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.

[46]  E. Ninio,et al.  PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[47]  P. Durrington,et al.  HDL, its enzymes and its potential to influence lipid peroxidation. , 1995, Atherosclerosis.

[48]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[49]  R. Rauramaa,et al.  HDL, HDL2, and HDL3 Subfractions, and the Risk of Acute Myocardial Infarction: A Prospective Population Study in Eastern Finnish Men , 1991, Circulation.

[50]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[51]  M. Elisaf,et al.  Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome , 2008 .

[52]  C. Tanaseanu,et al.  Plasma markers of endothelial dysfunction in type 2 diabetics. , 2006, European journal of internal medicine.

[53]  A. von Eckardstein,et al.  High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[54]  R. Rauramaa,et al.  HDL, HDL_2, and HDL_3 subfractions, and the risk of acute myocardial infarction , 1991 .